文献速递耳科与耳神经头颈外科

2型神经纤维瘤病相关神经鞘瘤病的人工耳蜗植入:长期听力结局

Cochlear Implantation in Neurofibromatosis Type 2-Related Schwannomatosis: Long-Term Hearing Outcomes.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-03-14

回顾性研究纳入2004至2018年间接受人工耳蜗植入且有至少1年随访的22例2型神经纤维瘤病伴同侧前庭神经鞘瘤患者。术后1年16例(73%)每日使用人工耳蜗,其中12例言语识别率≥40%(均值74±21.9%);末次随访(平均6±5年)时16例中12例仍每日使用,6例言语识别率≥40%。未发现1年良好表现或表现稳定性的预测因素。

要点

  • 术后1年73%(16/22)每日使用人工耳蜗,其中12例言语识别率≥40%。
  • 末次随访平均6±5年时,16例中12例仍每日使用,6例言语识别率≥40%。
  • 未发现1年良好表现或表现稳定性的预测因素。

核心结论

  • 2型神经纤维瘤病是严重影响生活质量的复杂疾病,人工耳蜗植入应始终根据个体情况逐一考虑。
  • 部分患者人工耳蜗植入可在较长时间内提供良好言语识别率,即使在治疗后或大肿瘤病例中亦然。

研究设计与样本

  • 回顾性研究,纳入2004至2018年间接受人工耳蜗植入且有至少1年随访的22例患者。
  • 患者分为人工耳蜗使用者与非使用者;使用者于术后1年在安静条件下评估无唇读的双音节词言语感知,此后每年评估。
  • 使用者按言语识别率分为≥40%或<40%两组,并记录人口学数据、治疗选择及肿瘤大小。

主要发现

  • 术后1年16例(73%)每日使用人工耳蜗。
  • 16例使用者中12例言语识别率≥40%(均值74±21.9%),3例为Koos IV期肿瘤。
  • 末次随访(平均随访6±5年)时,16例中12例仍每日使用植入装置,6例言语识别率≥40%。
  • 未发现1年良好表现或表现稳定性的预测因素。

临床怎么用

  • 作者认为,2型神经纤维瘤病患者的人工耳蜗植入应始终根据个体情况逐一考虑。
  • 作者认为,部分患者人工耳蜗植入可在较长时间内提供良好言语识别率,即使在治疗后或大肿瘤病例中亦然。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate long-term hearing outcomes following cochlear implantation in patients with neurofibromatosis type 2 and ipsilateral vestibular schwannoma. STUDY DESIGN: Retrospective study. SETTING: Tertiary general hospital. METHODS: Twenty-two patients undergoing cochlear implantation between 2004 and 2018 with at least 1 year of follow-up were included. Patients were categorized as "users" or "nonusers" of their cochlear implant (CI). For users, speech perception (disyllabic words) without lip-reading was assessed in quiet conditions 1-year postimplantation, and annually thereafter. CI users were classified into 2 groups on the basis of speech intelligibility (≥40% or <40%). Demographic data, treatment options, and tumor size were also recorded. RESULTS: One year after implantation, 16 (73%) patients used their CI daily. Twelve of these patients had a speech intelligibility ≥40% (mean: 74 ± 21.9%). Three had a Koos stage IV tumor. At the last visit (mean duration of follow-up: 6 ± 5 years), 12 of these 16 patients were still using their implant daily, and 6 had a speech intelligibility ≥40%. No predictive factors for good performance at 1 year or performance stability were identified. CONCLUSION: Neurofibromatosis type 2 is a complex disease profoundly affecting patient quality of life, and cochlear implantation should always be considered on a case-by-case basis. In some individuals, cochlear implantation can provide good speech intelligibility for extended periods, even posttreatment or in cases of large tumors.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Grenier B, Mosnier I, Ferrary E, et al. Cochlear Implantation in Neurofibromatosis Type 2-Related Schwannomatosis: Long-Term Hearing Outcomes. Otolaryngol Head Neck Surg. 2024. PMID: 38482961. doi:10.1002/ohn.702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。